OvaWatch® is a non-invasive test intended for use in assessing the risk of ovarian cancer for women with adnexal masses that have been considered indeterminate or benign by initial clinical assessment. With its superior negative predictive value, OvaWatch allows physicians to confidently choose the appropriate clinical management path for their patients.

Serious millennial chinese guy doctor in uniform listens symptoms of african american lady patient in office

OvaWatch report includes a new longitudinal monitoring feature to provide ongoing, point-in-time, personalized ovarian cancer assessments

The OvaWatch blood test combines the results of:

• Seven tumor biomarkers
• Age
• Menopausal status

Provides a single risk assessment score delivering a Negative Predictive Value of over 99%1

Giving you confidence in a low probability of malignancy result for both premenopausal and postmenopausal patients

OvaWatch Biomarkers

Protein/ Function chart

The OvaWatch report includes:

Utilize OvaWatch in your practice to confidently develop your 
management plans.

A single blood draw – which can be performed in a healthcare provider’s offices using our proprietary testing kit or at a number of national and regional laboratories – is all that is needed.

Download Our New Clinical Study Describing Real-World Evidence Supporting The Use Of OvaWatch® For The Clinical Management Of Adnexal Masses, Entitled:

“Validation of a Deep Neural Network-Based Algorithm Supporting Clinical Management of Adnexal Masses”

Planning for surgery?

Learn More About Ova1Plus

Utilize the OvaSuite portfolio of products and confidently move from assessment to action.

A single blood draw – which can be performed at a number of national and regional laboratories or in a healthcare provider's offices using our proprietary testing kit – is all that is needed. 

Contact us to learn more, order kits, or to locate one of our phlebotomy partners.